Institutional memory
The firm remembers why it said no
Every decision SV makes becomes part of the firm's memory — not just what was decided, but the evidence and reasoning behind it. When the world changes, Atlas knows which past judgements to reopen.
Reviewed February 2025
Decision: Do not pursueTarget X
Reasoning at the time
- Insufficient independent validation.
- Uncertain therapeutic window.
- No compelling company-formation path.
- Limited pharma validation.
What changed since
+7
publications
+2
independent validations
+3
patent families
+1
pharma programme
Two assumptions supporting the February 2025 decision no longer appear valid.
Then vs now
The same opportunity, re-evaluated
Why the judgement moved
Independent replication appeared
Two independent laboratories have since reproduced the key finding, directly addressing the “insufficient validation” concern recorded in February 2025.
Pharma validation emerged
A pharmaceutical programme against the target now exists, where there was none at the time of the original decision.
A company-formation path opened
Accumulated IP activity and investigator movement suggest a plausible formation path that did not previously exist.
Atlas surfaces this, unprompted, the moment the evidence shifts. The partner decides.